본문으로 건너뛰기
← 뒤로

PSMA-avid rib lesions in prostate cancer patients: differentiating false positives from metastatic disease.

European radiology 2025 Vol.35(9) p. 5337-5347

Woo S, Becker AS, Leithner D, Charbel C, Mayerhoefer ME, Friedman KP, Tong A, Murina S, Siskin M, Taneja SS, Zelefsky MJ, Wise DR, Vargas HA

📝 환자 설명용 한 줄

[OBJECTIVES] Prostate-specific membrane antigen (PSMA)-PET/CT has become integral to management of prostate cancer; however, PSMA-avid rib lesions pose a diagnostic challenge.

🔬 핵심 임상 통계 (초록에서 자동 추출 — 원문 검증 권장)
  • p-value p < 0.01

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Woo S, Becker AS, et al. (2025). PSMA-avid rib lesions in prostate cancer patients: differentiating false positives from metastatic disease.. European radiology, 35(9), 5337-5347. https://doi.org/10.1007/s00330-025-11514-3
MLA Woo S, et al.. "PSMA-avid rib lesions in prostate cancer patients: differentiating false positives from metastatic disease.." European radiology, vol. 35, no. 9, 2025, pp. 5337-5347.
PMID 40108014

Abstract

[OBJECTIVES] Prostate-specific membrane antigen (PSMA)-PET/CT has become integral to management of prostate cancer; however, PSMA-avid rib lesions pose a diagnostic challenge. This study investigated clinicopathological and imaging findings that predict metastatic etiology of PSMA-avid rib lesions.

[MATERIALS AND METHODS] Consecutive patients with prostate cancer that underwent PET/CT with [F]F-DCFPyL in 2021-2023 for newly diagnosed intermediate-/high-risk prostate cancer or recurrent/metastatic disease and had PSMA-avid rib lesions were included. Imaging findings assessed were: lesion number, PSMA expression (maximum standard uptake value (SUV), miPSMA score), CT features (sclerotic, lucent, fracture, no correlate), other sites of metastases, and primary tumor findings. A composite reference standard for rib lesion etiology (metastatic vs non-metastatic) based on histopathology, serial imaging, and clinical assessment was used.

[RESULTS] One hundred and seventy-five men (median 71 years, IQR 65-77) with PSMA-avid rib lesions were included; 47/175 (26.9%) had rib metastases. Only 1/47 (2.1%) of these patients had isolated rib metastasis without PSMA-avid metastases in other bones, nodes, or visceral organs; the other 46/47 (97.9%) patients with rib metastases also had other sites of PSMA-avid disease. Patients with rib metastases were older, had higher prostate-specific antigen levels, and higher-grade tumors (p < 0.01). Metastatic rib lesions had higher uptake (SUV, miPSMA), more commonly involved multiple ribs, and were more often sclerotic (p < 0.01); lucency/fractures were only seen in benign lesions.

[CONCLUSION] Several imaging and clinicopathological factors differed between PSMA-avid metastatic and benign lesions. Isolated rib lesions without other sites of metastasis are almost always benign. Careful assessment of CT features can help diagnose benign lesions.

[KEY POINTS] Question While prostate-specific membrane antigen (PSMA)-PET/CT has become integral to the management of prostate cancer, PSMA-avid rib lesions pose a diagnostic challenge. Findings Approximately a quarter of patients who had PSMA-avid rib lesions were metastatic. However, only 2.1% of them had isolated rib metastasis (without PSMA-avid metastases elsewhere). Clinical relevance Isolated PSMA-avid rib lesions are almost always benign when there is no evidence of metastatic disease elsewhere. Scrutinizing CT features can help diagnose benign PSMA-avid lesions with greater certainty.

MeSH Terms

Humans; Male; Prostatic Neoplasms; Aged; Positron Emission Tomography Computed Tomography; Glutamate Carboxypeptidase II; Bone Neoplasms; Diagnosis, Differential; Ribs; False Positive Reactions; Antigens, Surface; Radiopharmaceuticals; Retrospective Studies; Urea; Lysine

같은 제1저자의 인용 많은 논문 (5)